Boris Tchernychev
Ironwood Pharmaceuticals Inc., USA
Biography
Boris Tchernychev received his M.Sc. degree in Biophysics from the Department of Biology of Moscow State University. After completing his PhD in Biochemistry at the Weizmann Institute of Science and his postdoctoral training in the laboratory of B. Furie (Beth Israel Deaconess Medical Center), Boris joined the biotech industry where he spent the last 10 years supporting multiple drug discovery and development programs in different therapeutic areas. At present Boris is a Principal Investigator at Ironwood Pharmaceuticals, where his research is focused on further understanding the secretory and pain inhibitory mechanisms of the FDA-approved drug LINZESS (Guanylate Cyclase-C agonist linaclotide).
Abstract
Abstract : Pharmacology of the Guanylate Cyclase-C agonist Linaclotide